Amylyx Pharmaceuticals, Inc.
AMLX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658551
In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 6 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Amylyx Pharmaceuticals, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 131 | 169 | +38 |
| Shares | 81.7M | 109.7M | +28.0M (+34.3%) |
| Value | $523.6M | $1.49B | +$967.5M (+184.8%) |
New holders (57)
Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
Sold out (19)
Institutions that held Amylyx Pharmaceuticals, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Standard Life Aberdeen plc | 738,657 | $4.73M |
| J. Goldman & Co LP | 258,600 | $1.66M |
| Y-Intercept (Hong Kong) Ltd | 240,379 | $1.54M |
| Jane Street Group, LLC | 186,986 | $1.20M |
| American Century Companies Inc | 134,380 | $861.4K |
| Allostery Investments LP | 120,119 | $770.0K |
| Susquehanna International Group, LLP | 110,846 | $710.5K |
| Cantor Fitzgerald, L. P. | 50,000 | $320.5K |
| Jump Financial, LLC | 47,800 | $306.4K |
| Centiva Capital, LP | 45,464 | $291.4K |
| Squarepoint Ops LLC | 40,643 | $260.5K |
| Graham Capital Management, L.P. | 34,153 | $218.9K |
| Group One Trading, L.P. | 25,856 | $165.7K |
| Bridgeway Capital Management, LLC | 25,700 | $164.7K |
| Los Angeles Capital Management LLC | 23,320 | $149.5K |
| Marex Group plc | 20,000 | $128.2K |
| Tudor Investment Corp Et Al | 12,073 | $77.4K |
| Raymond James Financial Inc | 104 | $667 |
| Skopos Labs, Inc. | 42 | $270 |